<DOC>
	<DOCNO>NCT00701493</DOCNO>
	<brief_summary>The primary purpose study estimate bioavailability oral liquid formulation topiramate relative commercially available oral sprinkle capsule formulation healthy patient . If appropriate , bioequivalence oral liquid formulation sprinkle capsule formulation assess .</brief_summary>
	<brief_title>A Phase 1 Bioavailability Study Topiramate Oral Liquid Formulation Compared Marketed Sprinkle Capsule Formulation Healthy Adults</brief_title>
	<detailed_description>This randomize , open-label , 2-way crossover , single-center , relative bioavailability study healthy adult men woman . The study conduct 3 phase : pretreatment phase ( Days -14 -1 ) , 25-day open-label treatment phase , 7-day follow-up phase . Patients enter screen phase 14 day prior receive study treatment . During screen period , patient ' eligibility assess , physical examination safety evaluation perform . Eligible patient randomize baseline ( Day -1 ) receive topiramate oral liquid sprinkle capsule formulation accord 1 2 treatment sequence ( see Section 5 , Randomization Blinding ) . There 3 week washout period treatment . Initially , approximately 40 patient enrol study , order least 32 patient complete PK assessment . Patient confine study site evening Days -1 20 . Following 10-hour overnight fast , patient receive topiramate single 100-mg dose oral liquid formulation oral sprinkle capsule formulation accord sequence specify randomization schedule approximately 8 a.m. Days 1 21 . Serial blood sample collect estimation plasma topiramate concentration schedule time predose 96 hour postdose . Patients discharge study site Days 3 23 collection 48 hour postdose blood sample . Patients arrive study site 2 hour prior PK sample collection obtain 60 hour ( Days 3 23 ) , 76 hour ( Days 4 24 ) , 96 hour ( Days 5 25 ) postdose sample . Patients complete study Day 25 receive follow-up phone call Day 32 adverse event assessment . Safety tolerability assess throughout study . Patients randomly assign receive oral treatment : A B , B A . Treatment A : Topiramate 100 mg 20 mL 5 mg/mL liquid formulation Treatment B : Topiramate 100 mg 4 X 25-mg sprinkle capsule formulation There 3 week wash-out period treatment</detailed_description>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Body mass index ( BMI ) 19 32 kg/m2 , inclusive Women nonchildbearing potential practice birth control Have normal electrocardiogram ( ECG ) Be good health , opinion investigator Be sufficiently alert understand communicate intelligibly study staff ( i.e. , patient must able perform study procedure ) Agree limit methylxanthine consumption throughout study 2 methylxanthinecontaining substance Agree refrain ingesting product contain grapefruit , quinine , Seville orange study Agree refrain ingest antacid study Agree refrain ingest alcohol study Have sign inform consent document indicate study explain willing participate study . History significant renal , hepatic , gastrointestinal , hematologic , pulmonary , metabolic , thyroid , chronic disease Significant cardiovascular disease , include history myocardial infarction within past 2 year , cerebrovascular accident , clinically significant cardiac valvular disease , unstable angina , significantly abnormal ECG , arrhythmia , congestive cardiac failure History significant psychiatric disorder include schizophrenia , psychosis , panic disorder , major depression , suicidal attempt major affective disorder current dysthymia . If possible , investigator shall attempt confirm presence absence past psychiatric history subject 's primary care physician History raise intraocular pressure , glaucoma , otherwise risk acute narrowangle glaucoma Demonstrate significant active physical disease , acute chronic , within 7 day start study Liver enzyme ( alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] ) outside normal limit Women wish become pregnant within 2 month follow discontinuation study drug , breastfeed Require take prescription medication within 2 week dose Use overthecounter medication ( include aspirin , antacid , vitamin , herbal supplement ( e.g. , diuretic tea may impact renal function ) within 7 day dose end study Use hormonal contraceptive ( include oral , implanted , intrauterine device , patch ) hormonal replacement therapy within 3 month start screen 2 month study completion Use carbonic anhydrase inhibitor reason within 2 week start screen History alcohol drug abuse Testing positive HIV antibody , Hepatitis B antigen , Hepatitis C antibody Abnormal clinical laboratory value , unless review approve Sponsor 's medical monitor Use nicotinecontaining product , include tobacco product ( e.g. , cigarette , cigar , chew tobacco ) 3 month start screen end study History kidney stone Family history ( firstdegree relative ) kidney stone establish due know cause ( e.g. , hyperparathyroidism , medication ) History lactic acidosis chronic metabolic acidosis History hereditary acquire neurologic disease ( e.g. , epilepsy significant brain trauma ) Malignancy history malignancy within 5 year start screening , treat basal cell carcinoma skin Known contraindication hypersensitivity topiramate heparin Use medication know P450 enzyme inducer inhibitor ( e.g. , cimetidine rifampin ) , within 3 month dose . ( See Attachment 6 , Listing Medications That Are Known Cytochrome P450 Enzyme Inducers Inhibitors ) Any significant condition opinion investigator could interfere patient 's participation completion study Have receive experimental drug use experimental medical device within 30 day screen Employees investigator study center , direct involvement propose study study direction investigator study center , well family member employee investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Topiramate</keyword>
	<keyword>Topiramate oral liquid</keyword>
	<keyword>TOPAMAX Sprinkle capsule</keyword>
	<keyword>topiramate capsule</keyword>
</DOC>